Association Between Statin Use and Endometrial Cancer Survival

Obstetrics and Gynecology

Volumn 126, Issue 1, 2015, Pages 144-150

  Nevadunsky, Nicole S ^a   Van Arsdale, Anne ^a   Strickler, Howard D ^a   Spoozak, Lori A ^a   Moadel, Alyson ^a   Kaur, Gurpreet ^a   Girda, Eugenia ^a   Goldberg, Gary L ^a   Einstein, Mark H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; EZETIMIBE PLUS SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; ACETYLSALICYLIC ACID;

ADULT; CONFERENCE PAPER; DISEASE SPECIFIC SURVIVAL; DRUG USE; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; POLYPHARMACY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; AGED; COMPLICATION; ENDOMETRIUM TUMOR; EVALUATION STUDY; HYPERCHOLESTEROLEMIA; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL;

ADULT; AGED; ASPIRIN; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; POLYPHARMACY; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84932187602     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000926     Document Type: Conference Paper

References (25)

1. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008;25: 1769-81.
2. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins; an update. Fundam Clin Pharmacol 2005;19:117-25.
3. Nguyen DM, Richardson P, El-Serag HB. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology 2010;138:2260-6.
4. Chiu HF, Ho SC, Chang CC, Wu TN, Yang CY. Statins are associated with a reduced risk of gastric cancer: a populationbased case-control study. Am J Gastroenterol 2011;106:2098-103.
5. Khurana V, Sheth A, Caldito G, Barkin JS. Statins reduce the risk of pancreatic cancer in humans: a case-control study of half a million veterans. Pancreas 2007;34:260-5.
6. El-Serag HB, Johanson ML, Hachem C, Morgna RO. Statins are associated with a reduced risk for hepatocellular carcinoma in a large cohort of patients with diabetes. Gastroenterology 2011;136:1601-8.
7. Chiu HF, Ho SC, Chen CC, Yang CY. Statin use and the risk of liver cancer: a population-based case-control study. Am J Gastroenterol 2011;106:894-8.
8. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005;4:977-87.
9. Kwak B, Mulhapt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000;6:1399-402.
10. Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev 2012;64:102-46.
11. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, et al. Breast cancer growth prevention by statins. Cancer Res 2006;66:8707-14.
12. Khubakta P, Stollárová N, Skarda J, Zihlavníková K, Kajo K, Kapinová K, et al. Preventive effects of fluvastatin in rat mammary carcinogenesis. Eur J Cancer Prev 2013;22:352-7.
13. Björkhem-Berham L, Acimovic J, Torndal U, Parini P, Eriksson L. Lovastatin prevents carcinogenesis in a rat model for liver cancer. Effects of uiquinone supplementation. Anticancer Res 2010;30:1105-12.
14. Cao Z, Fan-Minoque H, Bellovin DI, Yevtodiyenko A, Arzeno J, Yang Q, et al. MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res 2011;71:2286-97.
15. Matsuura M, Suzuki T, Suzuki M, Tanaka R, Ito E, Saito T. Statin-medicated reduction of osteopontin expression induces apoptosis and cell growth arrest in ovarian clear cell carcinoma. Oncol Rep 2011;25:41-7.
16. Kochuparambil ST, Al-Husein B, Goc A, Soliman S, Somanath PR. Anticancer efficacy of simvastatin on prostate cancer cells and tumor xenografts is associated with inhibition of Akt and reduced prostate-specific antigen expression. J Pharmacol Exp Ther 2011;336:496-505.
17. Lavie O, Pinchev M, Rennert HS, Segev Y, Rennert G. The effects of statins on risk and survival of gynecological malignancies. Gynecol Oncol 2013;130:615-9.
18. Pecorelli S, Benedet JL, Creasman WT, Shepherd JH. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology, International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 1999;64:5-10.
19. Smith M, Lee N, Haney E, Carson S. Drug class review: HMGCoA reductase inhibitors (statins) and fixed-dose combination products containing statins. Portland (OR): Oregon Health and Science University; 2009.
20. Neilsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367: 1792-802.
21. Elmore G, Ioffe Y, Scoles DR, Karlan BY, Li AJ. Impact of statin therapy on survival in epithelial ovarian cancer. Gynecol Oncol 2008;111:102-5.
22. Schointuch MN, Gilliam TP, Stine JE, Han X, Zhou C, Gehrig PA, et al. Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer. Gynecol Oncol 2014;134:346-55.
23. Shai A, Renner HS, Renner G, Sagi S, Leviov M, Lavie O. Statins, aspirin and risk of thromboembolic events in ovarian cancer patients. Gynecol Oncol 2014;133:304-8.
24. Li AJ, Elmore RG, Chen IY, Karlan BY. Serum low-density lipoprotein levels correlate with survival in advanced stage epithelial ovarian cancers. Gynecol Oncol 2010;116:78-81.
25. Liu Y, Qin A, Li T, Qin X, Li S. Effect of statin on risk of gynecologic cancers: a meta-analysis of observational studies and randomized controlled trials. Gynecol Oncol 2014;133: 647-55.